Bayer earnings hit by tough farm market in fresh challenge for CEO
Adds details and CEO quote on overhaul from paragraph 6
By Ludwig Burger
FRANKFURT, Aug 6 (Reuters) -Bayer BAYGn.DE posted a 16.5% drop in quarterly adjusted earnings on Tuesday, becoming the latest agricultural chemicals supplier to be hit by weak demand due to lower grains prices and adding to the CEO's challenges in his second year in the job.
Bayer boss Bill Anderson has launched a push to speed up decision making and slash corporate bureaucracy to turn around the embattled industrial group, and job cuts gathered pace in the second quarter, according to the group's statement.
The group's April-to-June earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, fell to 2.1 billion euros ($2.3 billion), also dragged lower by negative foreign exchange effects, in line with an average analyst estimate posted on the company's website.
Bayer, which had close to 100,000 staff at the end of 2023, said it had cut the equivalent of 3,200 full-time jobs during the first six months of this year, marking an acceleration after cutting 1,500 jobs during the first quarter.
The CEO, who is slashing hierarchy levels to give product developers and sales people more power, has ruled out any staff reduction targets beyond saying cuts would be significant.
The voluntary redundancies, affecting managers primarily, have so far been consistent with a target to cut 2 billion euros in annual costs from 2026, Anderson said.
"This is exactly what we envisioned," he told a media call.
TOUGH FARMING MARKET
The tough farming market has been felt by rivals including Corteva CTVA.N of the United States, which last week cut full-year forecasts, hurt by lower prices.
A decline in agricultural commodity prices has forced many farmers to rein in their spending on crop chemicals.
BASF, another major competitor, has said herbicide and fungicide sale volumes declined during the April-to-June quarter, normally a key earnings-generating season for the industry.
Bayer confirmed its previous full-year earnings guidance, saying agriculture product margins would recover, excluding earnings from the glyphosate weedkiller, which has been subject to costly legal claims alleging that it causes cancer.
The company's shares were little changed at 0908 GMT, with Deutsche Bank analysts saying in a research note that better-than-expected pharmaceutical sales were broadly offset by a disappointing agriculture business.
Anderson said in March he would hold off for up to three years on previous preparations to break apart the German maker of pharmaceuticals, crop protection products and consumer health remedies.
His focus is instead on changing Bayer's management structure as well as on cutting debt and dealing with a massive wave of U.S. product liability lawsuits even though the U.S. environmental regulator has declared glyphosate safe to use.
Anderson, who became CEO in June 2023, has had a tumultuous start in the job marked by falling share prices and efforts to end the glyphosate litigation. The group also suffered a major setback in drug development late last year.
The CEO, however, clearly won a confidence vote at his first annual general meeting for Bayer in April. Earlier in the year, top-five shareholder Harris Associates came out in strong support for the CEO's course.
Reporting by Ludwig Burger;
Editing by Rachel More and Helen Popper
الأصول ذات الصلة
آخر الأخبار
إخلاء المسؤولية: تتيح كيانات XM Group خدمة تنفيذية فقط والدخول إلى منصة تداولنا عبر الإنترنت، مما يسمح للشخص بمشاهدة و/أو استخدام المحتوى المتاح على موقع الويب أو عن طريقه، وهذا المحتوى لا يراد به التغيير أو التوسع عن ذلك. يخضع هذا الدخول والاستخدام دائماً لما يلي: (1) الشروط والأحكام؛ (2) تحذيرات المخاطر؛ (3) إخلاء المسؤولية الكامل. لذلك يُقدم هذا المحتوى على أنه ليس أكثر من معلومات عامة. تحديداً، يرجى الانتباه إلى أن المحتوى المتاح على منصة تداولنا عبر الإنترنت ليس طلباً أو عرضاً لدخول أي معاملات في الأسواق المالية. التداول في أي سوق مالي به مخاطرة عالية برأس مالك.
جميع المواد المنشورة على منصة تداولنا مخصصة للأغراض التعليمية/المعلوماتية فقط ولا تحتوي - ولا ينبغي اعتبار أنها تحتوي - على نصائح أو توصيات مالية أو ضريبية أو تجارية، أو سجلاً لأسعار تداولنا، أو عرضاً أو طلباً لأي معاملة في أي صكوك مالية أو عروض ترويجية مالية لا داعي لها.
أي محتوى تابع للغير بالإضافة إلى المحتوى الذي أعدته XM، مثل الآراء، والأخبار، والأبحاث، والتحليلات والأسعار وغيرها من المعلومات أو روابط مواقع تابعة للغير وواردة في هذا الموقع تُقدم لك "كما هي"، كتعليق عام على السوق ولا تعتبر نصيحة استثمارية. يجب ألا يُفسر أي محتوى على أنه بحث استثماري، وأن تلاحظ وتقبل أن المحتوى غير مُعدٍ وفقاً للمتطلبات القانونية المصممة لتعزيز استقلالية البحث الاستثماري، وبالتالي، فهو بمثابة تواصل تسويقي بموجب القوانين واللوائح ذات الصلة. فضلاً تأكد من أنك قد قرأت وفهمت الإخطار بالبحوث الاستثمارية غير المستقلة والتحذير من مخاطر المعلومات السابقة، والذي يمكنك الاطلاع عليه هنا.
